Ask AI
ProCE Banner Activity

IMforte: Expanded Safety Analysis of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC

Conference Coverage
Slideset

An expanded safety analysis of phase III IMforte trial showed mostly low-grade adverse events and low rates of treatment discontinuation or interruption with lurbinectedin plus atezolizumab and no new or unexpected safety signals as first-line maintenance treatment of patients with ES-SCLC.

Released: November 13, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.